Videos

The adjunct clinical assistant professor, ophthalmology, Keck School of Medicine, University of Southern California discussed unmet needs with the current treatment landscape for DR.

The chief medical officer of Cellularity discussed the big picture implications of a new analysis of patient samples from legacy studies evaluating MLASC therapy in Crohn disease.

The professor of medicine and pediatrics at Washington University in St. Louis discussed the current investigative landscape for cell therapy in treating sarcomas.

The chief medical officer of Celularity discussed MLASC and a new analysis of gene and protein signatures from patients treated in legacy clinical trials that he presented at ASGCT’s 2023 conference.

The associate professor at MD Anderson Cancer Center discussed challenges with developing cell therapy for sarcoma and how TCR NK therapy's unique characteristics may prove useful.

The professor of medicine at University of California San Diego discussed the advent of gene therapy into the field of cardiac medicine.

The chief scientific officer at Omega Therapeutics discussed the importance of understanding more about and researching epigenetics.

The clinicians from MD Anderson Cancer Center and Washington University – St. Louis shared messages on sarcoma awareness.

The scientist at Senti Biosciences discussed preclinical research presented at ASGCT 2023.

The interventional cardiologist and professor, Duke University School of Medicine, discussed trends of new data on XC001.

The codirector of the MDA Clinic and professor of neurology at Johns Hopkins discussed updated data from the NURTURE study.

The chief scientific officer of LocanaBio discussed preclinical research presented at ASGCT 2023.

The chief medical officer of Forge Biologics discussed updated data from the phase 1/2 RESKUE clinical trial that she presented at ASGCT’s 2023 conference.

The assistant professor of microbiology at Penn Medicine discussed further research to be done with EGR2 and type 1 interferon.

The chief scientific officer at REGENXBIO discussed RGX-202 and the ongoing clinical trial.

The scientist II at Senti Biosciences discussed the potential of synthetic promoters to improve target specificity in AAV vector-based gene therapies in retinal diseases and beyond.

The pediatric gastroenterologist and professor in residence at University of California at San Francisco discussed biomarker findings from the phase 1/2 CAMPSIITE trial.

The associate director for gene therapy discovery at Precision Biosciences discussed preclinical research he presented at ASGCT’s 2023 conference.

The principal investigator at Seattle Children’s Research Institute discussed the continuing need to share preclinical research at conferences even as more gene therapies enter the clinic.

The chief scientific officer at Candel Therapeutics discussed progress in investigations with CAN-3110 and CAN-2409.

The principal investigator at Seattle Children’s Research Institute discussed the potential of new delivery methods and gene editing to overcome the limitations of AAV vector-based gene therapies.

The senior investigator at the National Cancer Institute Center for Cancer Research discussed unmet needs that remain and further research to be done.

The senior research fellow at Fred Hutch Cancer Center discussed research trends at the 2023 ASGCT meeting.

The director of the Center for Outcomes and Measurement in the Jefferson College of Rehabilitation Sciences at Thomas Jefferson University discussed the research she presented at the first Annual SCI Investor Symposium.

The professor of medicine at University of California San Diego discussed preclinical data on the LX2020 gene therapy.

The professor at Ohio State University and University of California – San Francisco discussed investigations with different delivery methods of GDNF gene therapy.

The director of therapeutic genome engineering, St. Jude Children’s Research Hospital discussed challenges with performing prime editing in cells.

The chief executive officer of Lineage Cell Therapeutics discussed findings related to its cell therapy OPC1 that the company presented at the first Annual SCI Investor Symposium.